https://www.selleckchem.com/products/cx-5461.html
008; OS, 100%/65%/0% at 12months, p0.001). In multivariate analysis including posttherapeutic cachexia-associated parameters, cancer cachexia phenotype (MFW vs. FW/NW) was an independent predictor of poor OS (hazard ratio 8.59, p0.001) along with an increase in neutrophil-lymphocyte ratio (p=0.028). Early cancer cachexia phenotypes were significantly associated with the survival of aUC patients treated with pembrolizumab. In contrast to the very early progression and poor prognosis in the MFW group, long-term survival can be exp
Like
Comment
Share
